Baxalta Inc (BXLT) : Tt International added new position in Baxalta Inc during the most recent quarter end. The investment management firm now holds 114,000 shares of Baxalta Inc which is valued at $4.8 Million , the company said in a statement filed on May 11, 2016 with the SEC.Baxalta Inc makes up approximately 1.95% of Tt International’s portfolio.
Other Hedge Funds, Including , Cornerstone Capital Management Holdings. boosted its stake in BXLT in the latest quarter, The investment management firm added 2,364 additional shares and now holds a total of 229,272 shares of Baxalta Inc which is valued at $9.7 Million. Baxalta Inc makes up approx 0.08% of Cornerstone Capital Management Holdings.’s portfolio.Bahl Gaynor Inc reduced its stake in BXLT by selling 22,986 shares or 50.09% in the most recent quarter. The Hedge Fund company now holds 22,903 shares of BXLT which is valued at $970,858. Baxalta Inc makes up approx 0.01% of Bahl Gaynor Inc’s portfolio.Janney Montgomery Scott reduced its stake in BXLT by selling 21,337 shares or 42.16% in the most recent quarter. The Hedge Fund company now holds 29,271 shares of BXLT which is valued at $1.2 Million. Baxalta Inc makes up approx 0.03% of Janney Montgomery Scott’s portfolio.Washington Trust Co reduced its stake in BXLT by selling 464 shares or 6.37% in the most recent quarter. The Hedge Fund company now holds 6,817 shares of BXLT which is valued at $280,656. Baxalta Inc makes up approx 0.02% of Washington Trust Co’s portfolio.State Of New Jersey Common Pension Fund D boosted its stake in BXLT in the latest quarter, The investment management firm added 900,000 additional shares and now holds a total of 1,211,000 shares of Baxalta Inc which is valued at $50.8 Million. Baxalta Inc makes up approx 0.23% of State Of New Jersey Common Pension Fund D’s portfolio.
Baxalta Inc opened for trading at $42.33 and hit $42.89 on the upside on Monday, eventually ending the session at $42.82, with a gain of 1.01% or 0.43 points. The heightened volatility saw the trading volume jump to 1,22,43,940 shares. Company has a market cap of $29,269 M.
On the company’s financial health, Baxalta Inc reported $0.47 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $0.46. The company had revenue of $1548.00 million for the quarter, compared to analysts expectations of $1474.42 million. The company’s revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.40 EPS.
Baxalta Incorporated is a biopharmaceutical company. The Company develops manufactures and markets a portfolio of treatments for hemophilia and other bleeding disorders immune deficiencies alpha-1 antitrypsin deficiency burns and shock and other chronic and acute medical conditions. The Company also focuses on disease areas including oncology as well as technology platforms including gene therapy and biosimilars. The Company has a portfolio of various therapies that address unmet medical needs across various disease areas including hemophilia immunology and oncology. The Company’s products include ADVATE RECOMBINATE HEMOFIL M Immunate Immunine PROTHROMPLEX TOTAL RIXUBIS FACTOR VII NF BEBULIN FEIBA OBIZUR GAMMAGARD LIQUID GAMMAGARD S/D Subcuvia HYQVIA FLEXBUMIN BUMINATE ARALAST NP GLASSIA NP CEPROTIN and ANTITHROMBIN III IMMUNO.